Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparison Between Gilteritinib in Phase 3 Trials Versus Real-World External Comparator Cohort of Relapsed/Refractory (R/R) FLT3m+ Acute Myeloid Leukemia (AML) Patients After Hematopoietic Stem Cell Transplantation (HSCT)

NCT06734585 is registered in ClinicalTrials.gov with Astellas Pharma Singapore Pte. Ltd. as lead sponsor.

NCT NCT06734585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06734585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparison Between Gilteritinib in Phase 3 Trials Versus Real-World External Comparator Cohort of Relapsed/Refractory (R/R) FLT3m+ Acute Myeloid Leukemia (AML) Patients After Hematopoietic Stem Cell Transplantation (HSCT)
Lead sponsor
Astellas Pharma Singapore Pte. Ltd.
Phase
Observational
Overall status
Completed
Start date
January 9, 2025
Completion date
July 14, 2025
Enrollment
114 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia